-$0.09 Earnings Per Share Expected for MannKind Co. (NASDAQ:MNKD) This Quarter

Equities analysts forecast that MannKind Co. (NASDAQ:MNKDGet Rating) will announce earnings per share (EPS) of ($0.09) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for MannKind’s earnings, with estimates ranging from ($0.10) to ($0.08). MannKind reported earnings of ($0.05) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 80%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that MannKind will report full year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.41) to ($0.26). For the next year, analysts forecast that the firm will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.14) to $0.09. Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover MannKind.

MannKind (NASDAQ:MNKDGet Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $11.99 million during the quarter, compared to analyst estimates of $10.44 million. During the same period last year, the business earned ($0.05) EPS.

MNKD has been the subject of a number of analyst reports. HC Wainwright decreased their price objective on MannKind from $6.50 to $6.00 and set a “buy” rating for the company in a research note on Monday, February 28th. StockNews.com upgraded MannKind to a “sell” rating in a report on Saturday, April 30th. Finally, Zacks Investment Research raised MannKind from a “sell” rating to a “hold” rating in a research report on Saturday, May 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.00.

In other news, Director Anthony C. Hooper purchased 40,000 shares of MannKind stock in a transaction dated Monday, February 28th. The stock was purchased at an average cost of $2.71 per share, for a total transaction of $108,400.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alejandro Galindo bought 36,900 shares of the business’s stock in a transaction that occurred on Monday, February 28th. The stock was bought at an average price of $2.71 per share, with a total value of $99,999.00. The disclosure for this purchase can be found here. Company insiders own 2.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in MNKD. Macquarie Group Ltd. bought a new stake in shares of MannKind during the 3rd quarter valued at $26,000. Oakworth Capital Inc. bought a new stake in shares of MannKind in the 1st quarter worth about $25,000. Russell Investments Group Ltd. bought a new stake in MannKind during the 4th quarter valued at about $39,000. PYA Waltman Capital LLC bought a new stake in MannKind during the 4th quarter valued at about $43,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of MannKind in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 43.57% of the company’s stock.

MannKind stock opened at $3.19 on Thursday. The business has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $3.87. MannKind has a one year low of $2.49 and a one year high of $5.53. The company has a market capitalization of $805.68 million, a PE ratio of -8.62 and a beta of 1.97.

About MannKind (Get Rating)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.

Featured Articles

Get a free copy of the Zacks research report on MannKind (MNKD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.